Myriad settles BRCA litigation following Federal Circuit ruling
Myriad Genetics has settled litigation with three of the laboratories it accused of infringing patents on two genes associated with breast and ovarian cancer, following a Federal Circuit ruling last month confirming some of its claims were patent ineligible
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
